EFFECTS OF WALKING MEDITATION ON BALANCE PERFORMANCE IN INDIVIDUALS WITH PERIPHERAL NEUROPATHY FROM TYPE 2 DIABETES
- Conditions
- Peripheral neuropathy,Diabetes mellitus type 2
- Registration Number
- TCTR20190210001
- Lead Sponsor
- The graduate school of Srinakharinwirot University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 28
1.Never practice walking meditation.
2. The evaluated scores by the Michigan Neuropathy Screening Instrument (MNSI) in the section of a self-administered questionnaire have to be ≥7 points, and/or that in the section of clinical examination have to be ≥ 2points.
3. Able to walk independently without gait aids.
4. Able to understand and follow the instructions.
5. Be informed and sign the informed consent before the enrollment.
1. The diseases that affect the central nervous system such as Parkinson's disease, hemiparesis, etc.
2. Partial or total amputation of lower extremities.
3. Body mass index (BMI) ≥ 40 kg/m2
4. Attend another exercise during the study.
5. Got a contraindicated complication for exercise as mentioned in the American Diabetes Association Guidelines such as systematic infection etc.
6. Uncontrolled hypertension, severe cardiovascular, severe respiratory conditions.
7. Severe foot problems that affect mobility or walking such as acute foot ulcer or foot condition that need orthotics or special shoes.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Timed up and go test 4 weeks The test will be performed by asking subject to rise from a chair, walk three meters, turn, walk ba,Functional reach test 4 weeks The researcher will measure the displacement of reaching from the starting position to the maximum r,eye-open and eye-closed stand 4 weeks The time that subject can maintain balance will be recorded until a maximum of 30 seconds long. Subj
- Secondary Outcome Measures
Name Time Method Duration of last dose of MPA before undergoing plasmapheresis 1 years MPA AUC